相关实验视频

Updated: Jun 28, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在肺癌的伴随诊断测试开发中存在挑战

Stefano Lucà¹, Alessandra Celi², Alessandro Cioce¹

¹Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università Degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.

Expert review of anticancer therapy

|October 11, 2025

概括

准确评估ALK和PD-L1生物标志物对于非小细胞肺癌 (NSCLC) 治疗至关重要. 综合生物标志物测试指导个性化治疗,改善临床管理,以获得更好的患者结果.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断学
个性化医疗是个性化的医疗.

背景情况:

非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
针对NSCLC的个性化治疗依赖于对预测生物标志物的准确评估.
伴随诊断 (CDx) 测试对于指导NSCLC临床决策至关重要.

研究的目的:

突出ALK和PD-L1作为NSCLC预测生物标志物的重要性.
讨论伴随诊断在NSCLC治疗中的作用.
强调生物标志物评估的综合方法的好处.

主要方法:

对PD-L1和ALK的当前诊断方法的审查.
讨论免疫组织化学 (IHC),光在位杂交 (FISH) 和下一代测序 (NGS).
在NSCLC治疗中分析PD-L1和ALK的预测值.

主要成果:

PD-L1表达预测了对免疫检查点抑制剂的反应,尽管不是普遍的.
在IHC查后通过FISH或NGS确认的ALK重组,指导ALK抑制剂治疗.
将IHC与分子技术相结合,可以提高诊断准确度.

结论:

PD-L1和ALK是NSCLC患者管理的关键预测生物标志物.
结合IHC和分子测试 (FISH/NGS) 的综合方法优化了治疗选择.
基于综合生物标志物评估的定制治疗策略改善了NSCLC的临床结果.

关键词:

阿尔克 (ALK) 是一个在PD-L1中.伴随性诊断试验伴随性诊断试验免疫化学免疫化学免疫疗法免疫疗法非小细胞肺癌的肺癌.针对性治疗的目标治疗.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

相关概念视频

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...